ECCO 2022

Microbiota manipulation: Still a lot to learn

Combined endpoints as new therapy goals

Light at the end of the Pouchitis track

Combination trials open a new door in IBD treatment

The potential of histology in Crohn´s disease and how…

The first combination therapy trial

Combination of biologics

Filgotinib for fistulizing disease

Infliximab withdrawl leeds to a higher risk of…

SPARE study in ECCO 2022

FMT in UC - still far away from the success story

Combination of biologics - finally arrived in IBD!?

Is stopping of therapy an option in CD?

Proactive TDM

Withdrawal of infliximab or anti-metabolite therapy in…

Is the speedity of the steroid tapering important…

The interleukin-17 conundrum

FMT is not a promising option for UC patients

Will we improve the management of IBD by combining…

Ustekinumab for fistulizing disease

Combination with different classes of drugs in moderate…

A new opportunity for proactive TDM disease control

How to deescalate treatment in CD?

A negative control trial for FMT in UC

Proactive TDM or SOC for monitoring infliximab…

Una nuova opportunità per i TDM nel controllo proattivo…

FMT ist kein vielversprechender Ansatz für UC-Patienten

Ist der Therapiestopp eine Option in CD?

Allons nous améliorer la prise en charge des MICI en…

Wann Beendigung von Infliximab oder Immunmodulatoren…

FMT w colitis ulcerosa - wciąż daleko od sukcesu

מחקר SPARE ב ECCO 2022

Kombination von Biologika - endlich bei IBD…

Un essai négatif sur la transplantation de microbiote…

Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την…

Das Interleukin-17 Rätsel

Du nouveau sur l’allégement thérapeutique au cours de…

Προληπτική μέτρηση των θεραπευτικών επιπέδων του…

Il primo trial di terapia biologica di combinazione

Inflammatory bowel disease and cancer risk

COVID-19: still a moving target!

Which IBD patients have a higher risk of safety…

Can we translate rheumatoid arthritis to ulcerative…

The heart is apparently safe with continuous Ozanimod…

A touch of the near future in IBD treatment

Il cuore sembra essere apparentemente al sicuro durante…

Muttermilch beeinflusst das IBD-Risiko

The race is on IL-23 – exciting data for CD and UC

Vedolizumab: promising data for pouchitis and IBD in…

Fistulizing Crohn‘s disease - new treatment options…

Efficacy update on JAKis

Vedolizumab in chronic pouchitis - a new chapter in…

New ways of treatment

Anti-IL-23 - a turning point?

Vedolizumab is effective in chronic pouchitis after…

Selective IL-23 blockade

Great news on pouchitis treatment - vedolizumab…

JAK inhibition

New opportunity in pouchitis treatment

Upadacitinib - will it be the game changer in UC?

Anti-IL-23 - eine Zeitenwende?

Wedolizumab w pouchitis - początek nowego rozdziału w…

Selektive IL-23 Blockade

Nuevos caminos en el tratamiento

JAK-Inhibition

Upadacitinib - nowy lek, duże nadzieje

Guselkumab come terapia di mantenimento

Natural history of anal ulcerations in pediatric-onset…

New therapy goals: urgency and disease clearance

Histological findings in mirikizumab treatment

New therapeutic goals in UC

New goals for IBD

Patient relevant outcomes also show efficacy of…

Histoire naturelle de la maladie de Crohn ano-périnéale…

Nuevas objetivos en las EII

Urgency und Disease Clearance

The efficacy of COVID-19 vaccines in IBD - what's new?

Skuteczność szczepień przeciw COVID-19 w IBD - nowe…

Ultrasound as a predictor of treatment response

Ultraschall als Prädiktor des Therapieansprechens

ECCO guidelines on pregnancy

ECCO Richtlijnen zwangerschap